Laterality changes the first clue, but tissue diagnosis and anatomic stage determine the next move.
Primary diagnostic imageAn infiltrating colorectal carcinoma narrows the lumen and can present with bleeding, iron deficiency, altered caliber, or obstruction.Netha Hussain / Wikimedia Commons (CC BY-SA 3.0). SourceCC BY-SA 3.0
Contrast right-sided occult bleeding with left-sided obstructive presentations.
Separate average-risk screening from diagnostic colonoscopy in symptomatic patients.
Use stage, resectability, and tumor biomarkers to frame treatment.
Recognize iron-deficiency anemia and Streptococcus gallolyticus bacteremia as colon evaluation clues.
Use CEA for post-treatment monitoring rather than screening or tissue diagnosis.
Progression ladder
Follow progression from driver to treatment
The figure separates tumor initiation, progression, staging, and treatment decisions.
Quick check
A 67-year-old man has progressive fatigue, hemoglobin 9.1 g/dL, MCV 72 fL, ferritin 7 ng/mL, and no visible blood in stool. He has never had colorectal cancer screening.
Which next step best addresses the most dangerous unifying diagnosis?
Reason it through
What pattern identifies iron deficiency?Microcytosis plus a low ferritin supports depleted iron stores.
Why can a proximal tumor stay clinically quiet?The right colon has a wider lumen and liquid contents, so chronic occult bleeding may precede obstruction.
Does this patient still belong in the screening pathway?No. Iron-deficiency anemia makes the colon evaluation diagnostic.
In an older adult, unexplained iron deficiency is colon cancer until the source is found.
Know who is average risk
Screening guidance applies to average-risk asymptomatic adults; high-risk conditions require a separate plan.
The USPSTF recommends colorectal cancer screening beginning at age 45 for average-risk adults and continuing routinely through age 75.
For ages 76 through 85, screening is selective and depends on prior screening, overall health, life expectancy, and preferences.
Positive non-colonoscopy screening tests require follow-up colonoscopy to realize the benefit of screening.
Select the statement that belongs to average-risk screening.
Screen the well; scope the symptomatic.
Move from suspicion to stage
Symptoms change the task from screening to diagnosis, and treatment planning begins only after tissue and extent are established.
Colonoscopy visualizes the lesion, obtains biopsy tissue, and evaluates the remaining colon for synchronous neoplasia.
After adenocarcinoma is confirmed, stage with appropriate cross-sectional imaging and determine local invasion, regional nodes, distant spread, and whether metastatic disease is resectable.
Obtain a baseline CEA after diagnosis when useful for later comparison, but never use a normal CEA to exclude cancer.
Establish histology and inspect the rest of the colon when technically feasible.
Use pathology and imaging to assign local, nodal, and metastatic stage and assess resectability.
Test mismatch repair or microsatellite status and obtain additional predictive biomarkers when systemic therapy is contemplated.
Integrate stage, resectability, tumor biology, comorbidity, and patient goals.
Read the side from the symptom
Tumor location predicts the earliest clinical signal because luminal caliber and stool consistency differ across the colon.
Right-sided cancers grow in a capacious lumen with liquid contents and commonly cause occult blood loss, iron-deficiency anemia, fatigue, and weight loss before obstruction.
Left-sided cancers narrow a smaller lumen containing formed stool and more often cause change in bowel habits, decreasing stool caliber, cramping, hematochezia, or obstruction.
Either side can bleed, obstruct, metastasize, or present nonspecifically; laterality is a probability tool, not a rule-out test.
Contrast the classic presentations.
Occult bleeding, iron-deficiency anemia, fatigue, and a later palpable mass; obstruction tends to occur later.
Tenesmus, urgency, rectal bleeding, and a sense of incomplete evacuation.
Unintentional weight loss, persistent bleeding, unexplained anemia, bowel-habit change, or an abdominal mass.
Right bleeds silently; left blocks loudly.
Map the major risk neighborhoods
Risk rises through acquired exposures, chronic mucosal inflammation, prior neoplasia, and inherited susceptibility.
Colorectal cancer is one of the most common cancers worldwide; incidence rises with age, although younger-onset disease is increasing.
Advancing age is a major population risk, although incidence in younger adults has increased and symptoms at any age still require evaluation.
Important personal risks include adenomatous polyps or prior colorectal cancer, long-standing colonic inflammatory bowel disease, obesity, physical inactivity, smoking, and higher alcohol or processed-meat exposure.
Family history and syndromes such as Lynch syndrome and familial adenomatous polyposis can justify earlier and more intensive surveillance than average-risk schedules.
Place each risk signal in its clinical neighborhood.
Older age, obesity, inactivity, tobacco, alcohol, and dietary patterns associated with colorectal carcinogenesis.
Long-standing ulcerative colitis or Crohn colitis increases risk through chronic mucosal injury and dysplasia.
Advanced adenoma or prior colorectal cancer predicts future metachronous neoplasia and changes surveillance.
Lynch syndrome, familial adenomatous polyposis, and a strong family history require risk-specific strategies.
Streptococcus gallolyticus bacteremia or endocarditis should prompt evaluation for occult colorectal neoplasia.
Scale treatment with disease extent
The curative core is complete resection when disease is localized and resectable; systemic therapy gains importance with nodal and distant spread.
Stage I colon cancer is generally treated with oncologic surgical resection without routine adjuvant chemotherapy.
Stage II colon cancer is resected; adjuvant therapy is individualized for high-risk features, and mismatch repair status informs the discussion.
Stage III colon cancer generally receives resection plus adjuvant oxaliplatin-based chemotherapy when the patient can tolerate it.
Stage IV care depends on resectability and molecular findings: selected limited metastases may be resected or ablated, while unresectable disease receives biomarker-directed systemic therapy, including immunotherapy for MSI-H or dMMR tumors.
For selected metastatic regimens, induction is the initial intensive phase used to gain control or enable resection; maintenance is a planned lower-intensity continuation after response or stable disease. Adjuvant therapy after curative resection is time-limited and is not maintenance.
Place each state from localized to disseminated disease.
Stage tells you how far; biomarkers tell you which systemic lever may work.
Reveal what each test can and cannot do
The common error is assigning a screening, diagnostic, staging, or surveillance test a job it cannot perform.
Colonoscopy with biopsy diagnoses the primary lesion; imaging and operative pathology establish extent.
CEA can support prognosis and post-treatment surveillance when elevated at baseline, but it is neither a screening test nor proof of recurrence by itself.
A rising CEA should trigger clinical and imaging evaluation rather than automatic treatment without localization.
Open each test card to expose its proper role.
FIT, stool DNA-FIT, colonoscopy, CT colonography, and selected sigmoidoscopy strategies are options for asymptomatic average-risk adults.
An abnormal non-colonoscopy result must be completed with colonoscopy.
Directly evaluates bleeding, iron-deficiency anemia, bowel-habit change, obstruction, or another alarm feature and permits biopsy.
Symptoms override the routine screening calendar.
Cross-sectional imaging and surgical pathology define local, nodal, and distant disease and help determine resectability.
Stage is an anatomic treatment map.
A baseline and serial values can help monitor treated disease in appropriate patients.
Do not use CEA to screen, exclude cancer, or replace imaging and pathology.
Stage 1 of 3: Overview
Overview
Colorectal Cancer: Find It, Stage It, Treat It
Symptoms change the task from screening to diagnosis, and treatment planning begins only after tissue and extent are established.
Step by step
Move from suspicion to stage
1Recognize a diagnostic clueSymptoms, iron-deficiency anemia, obstruction, or Streptococcus gallolyticus bacteremia trigger colon evaluation.
2Perform complete colonoscopy with biopsyEstablish histology and inspect the rest of the colon when technically feasible.
3Define anatomic extentUse pathology and imaging to assign local, nodal, and metastatic stage and assess resectability.
4Characterize the tumorTest mismatch repair or microsatellite status and obtain additional predictive biomarkers when systemic therapy is contemplated.
Why it mattersObtain a baseline CEA after diagnosis when useful for later comparison, but never use a normal CEA to exclude cancer.
RememberIn an older adult, unexplained iron deficiency is colon cancer until the source is found.
Work through the oncology pathway
Five patients arrive through different doors: silent blood loss, obstruction, bacteremia, routine prevention, and postoperative surveillance.
Cross out stage mismatches and highlight the treatment-changing clue. Each case separates biology, stage, and intent.
A 69-year-old woman reports fatigue and 5-kg weight loss. Hemoglobin is 8.8 g/dL, MCV is 70 fL, ferritin is low, and fecal occult blood is positive. She denies gross bleeding.
Which tumor location and presentation are most likely?
Reason it through
Which laboratory value makes chronic blood loss concrete?The low ferritin confirms depleted iron stores.
Which side can expand before blocking?The wider right colon with liquid contents can harbor a large lesion before obstruction.
What test closes the diagnostic gap?Colonoscopy with biopsy.
Occult blood plus iron deficiency points upstream until proven otherwise.
Which laboratory value makes chronic blood loss concrete?Which side can expand before blocking?
Which laboratory value makes chronic blood loss concrete?The low ferritin confirms depleted iron stores.
Which side can expand before blocking?The wider right colon with liquid contents can harbor a large lesion before obstruction.
What test closes the diagnostic gap?Colonoscopy with biopsy.
A 73-year-old man has progressive constipation, pencil-thin stools, cramping, abdominal distention, and no flatus for 18 hours. CT shows an annular descending-colon mass with proximal dilation.
Which mechanism best explains this presentation?
Reason it through
What symptom identifies a mechanical endpoint?Obstipation with distention indicates high-grade luminal blockage.
Why does the distal colon block earlier?Its lumen is narrower and its contents are more solid.
What immediate principle outranks elective staging?Stabilize and manage the obstruction while completing oncologic evaluation.
The left colon turns tumor growth into a plumbing problem.
What symptom identifies a mechanical endpoint?Why does the distal colon block earlier?
What symptom identifies a mechanical endpoint?Obstipation with distention indicates high-grade luminal blockage.
Why does the distal colon block earlier?Its lumen is narrower and its contents are more solid.
What immediate principle outranks elective staging?Stabilize and manage the obstruction while completing oncologic evaluation.
A 61-year-old man is treated for Streptococcus gallolyticus endocarditis. He has no bowel symptoms and his last colonoscopy was more than 10 years ago.
Which follow-up is most appropriate after stabilization?
Reason it through
What makes the organism more than a bloodstream isolate?Its established association with colorectal adenomas and carcinoma.
Is this average-risk screening?No. The bacteremia is a clinical clue prompting diagnostic evaluation.
Which test can visualize and biopsy a lesion?Colonoscopy.
S. gallolyticus in blood earns the colon a direct look.
What makes the organism more than a bloodstream isolate?Is this average-risk screening?
What makes the organism more than a bloodstream isolate?Its established association with colorectal adenomas and carcinoma.
Is this average-risk screening?No. The bacteremia is a clinical clue prompting diagnostic evaluation.
Which test can visualize and biopsy a lesion?Colonoscopy.
A healthy 45-year-old woman has no gastrointestinal symptoms, inflammatory bowel disease, prior polyps, or family history of colorectal cancer. She asks whether she should wait until age 50.
Which recommendation is most appropriate?
Reason it through
Does she have a symptom that changes this to diagnosis?No. She is asymptomatic.
Does she have a feature requiring a hereditary schedule?No high-risk feature is given.
What threshold applies?Average-risk screening begins at age 45.
Forty-five is the average-risk starting line.
Does she have a symptom that changes this to diagnosis?Does she have a feature requiring a hereditary schedule?
Does she have a symptom that changes this to diagnosis?No. She is asymptomatic.
Does she have a feature requiring a hereditary schedule?No high-risk feature is given.
What threshold applies?Average-risk screening begins at age 45.
A 58-year-old man underwent complete resection of stage III colon adenocarcinoma and completed adjuvant chemotherapy. His CEA was elevated before surgery, normalized afterward, and is now rising on serial checks. He feels well.
Which interpretation is most accurate?
Reason it through
Why is CEA informative in this patient?It was elevated at baseline and normalized after definitive treatment.
What can CEA not tell you?It cannot localize disease or prove the cause of the rise.
What completes the signal?Appropriate imaging and clinical evaluation, with tissue confirmation when needed.
CEA rings the surveillance alarm; it does not identify the fire.
Why is CEA informative in this patient?What can CEA not tell you?
Why is CEA informative in this patient?It was elevated at baseline and normalized after definitive treatment.
What can CEA not tell you?It cannot localize disease or prove the cause of the rise.
What completes the signal?Appropriate imaging and clinical evaluation, with tissue confirmation when needed.
Tumor-board pivot
Choose the finding that changes the pathway
Choose the feature that changes diagnosis, stage, or treatment intent.
Which next step best addresses the most dangerous unifying diagnosis?
Key finding. A 67-year-old man has progressive fatigue, hemoglobin 9.1 g/dL, MCV 72 fL, ferritin 7 ng/mL, and no visible blood in stool. He has never had colorectal cancer screening.
Answer. Diagnostic colonoscopy
Why. Unexplained iron-deficiency anemia in an older adult can reflect occult right-sided colorectal cancer and requires diagnostic evaluation.
Board rule. In an older adult, unexplained iron deficiency is colon cancer until the source is found.
Rapid review
Three questions to check
Which next step best addresses the most dangerous unifying diagnosis?
Diagnostic colonoscopy. Unexplained iron-deficiency anemia in an older adult can reflect occult right-sided colorectal cancer and requires diagnostic evaluation.
Which laboratory value makes chronic blood loss concrete?
The low ferritin confirms depleted iron stores.
Which side can expand before blocking?
The wider right colon with liquid contents can harbor a large lesion before obstruction.
Resident physician and founding medical reviewer at Bone Wizardry, focused on clinical accuracy, clear diagnostic reasoning, and practical board-oriented teaching across the curriculum.
